Skip to main content
OpenTrials
Completed

NCT Number: NCT00552305

To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

The purpose of this trial is to determine whether lacosamide is safe and effective for long-term use in patients with partial-seizures from epilepsy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Partial Epilepsies Brain Diseases Central Nervous System Diseases Epilepsies, Partial Epilepsy Nervous System Diseases

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Bonn, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Completion of parent clinical trial for treatment of partial seizures.

Exclusion criteria

  • Receiving any study drug or experimental device other than lacosamide.
  • Meets withdrawal criteria for parent trial or experiencing ongoing serious adverse event.

Treatment and study plan

Lacosamide

Drug

50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing throughout the trial

Other names: Vimpat

Primary outcomes

  1. Number of Subjects Reporting at Least 1 Treat-Emergent Adverse Event (TEAE) During the Treatment Period (up to 8 Years)

    Time frame: During the Treatment Period (up to 8 years)

    Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

  2. Number of Subjects Prematurely Discontinuing Due to a Treatment-Emergent Adverse Event (TEAE) During the Treatment Period (up to 8 Years)

    Time frame: During the Treatment Period (up to 8 years)

    Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

  3. Number of Subjects Reporting at Least 1 Serious Adverse Event (SAE) During the Treatment Period (up to 8 Years)

    Time frame: During the Treatment Period (up to 8 years)

    A serious adverse event is any untoward medical occurrences in a subject administered study treatment, whether or not the event is related to treatment, with at least one of the follow outcomes: death, life-threatening, initial inpatient hospitalization or prolongation of hospitalization, significant or persistent disability/incapacity, congenital anomaly/birth defect, or an important medical event that may jeopardize the subject and require a medical/surgical intervention.

Secondary outcomes

  1. Median Percentage Change From Baseline in 28-day Seizure Frequency During the Treatment Period (up to 8 Years)

    Time frame: Baseline, End of Treatment Period (up to 8 years)

    Median percentage change is the median value with respect to the percent change from Baseline across the population of subjects. Percentage change is calculated as 100 times the difference of the seizure frequency for the treatment period and the Baseline seizure frequency divided by the baseline seizure frequency.

    Negative changes from Baseline indicate an improvement (i.e., a reduction) in 28-day seizure frequency.

  2. Percentage of at Least 50% Responders During the Treatment Period (up to 8 Years)

    Time frame: Treatment Period (up to 8 years)

    At least 50 percent response is based on the percentage reduction in 28-day seizure frequency during the Treatment Period of the open-label extension relative to the Baseline Phase of the prior study. This endpoint reflects the percentage of subjects with at least 50% reduction (ie, at least 50% change) in 28-day partial onset seizure frequency

Sponsors and collaborators

Lead sponsor

UCB Pharma

Industry

Registry information

Official study title

An Open-label Extension Trial to Determine Tolerability and Efficacy of Long-term Oral SPM 927 as Adjunctive Therapy in Patients With Partial Seizures

Important dates

Study start
2001
Primary completion
2010
Study completion
2010
First posted
Nov 1, 2007
Registry last updated
Jul 17, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.